310 related articles for article (PubMed ID: 21468919)
41. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation.
Chieng N; Aaltonen J; Saville D; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):47-54. PubMed ID: 18644443
[TBL] [Abstract][Full Text] [Related]
42. Miniaturized approach for excipient selection during the development of oral solid dosage form.
Raijada D; Müllertz A; Cornett C; Munk T; Sonnergaard J; Rantanen J
J Pharm Sci; 2014 Mar; 103(3):900-8. PubMed ID: 24436033
[TBL] [Abstract][Full Text] [Related]
43. Characterization and evaluation of miconazole salts and cocrystals for improved physicochemical properties.
Tsutsumi S; Iida M; Tada N; Kojima T; Ikeda Y; Moriwaki T; Higashi K; Moribe K; Yamamoto K
Int J Pharm; 2011 Dec; 421(2):230-6. PubMed ID: 21983091
[TBL] [Abstract][Full Text] [Related]
44. Study of process induced polymorphic transformations in fluconazole drug.
Desai SR; Dharwadkar SR
Acta Pol Pharm; 2009; 66(2):115-22. PubMed ID: 19719043
[TBL] [Abstract][Full Text] [Related]
45. Differences in the interaction between aryl propionic acid derivatives and poly(vinylpyrrolidone) K30: A multi-methodological approach.
Gashi Z; Censi R; Malaj L; Gobetto R; Mozzicafreddo M; Angeletti M; Masic A; Di Martino P
J Pharm Sci; 2009 Nov; 98(11):4216-28. PubMed ID: 19645003
[TBL] [Abstract][Full Text] [Related]
46. Nanocomposites of 2-arylpropionic acid drugs based on Mg-Al layered double hydroxide for dissolution enhancement.
Berber MR; Minagawa K; Katoh M; Mori T; Tanaka M
Eur J Pharm Sci; 2008 Nov; 35(4):354-60. PubMed ID: 18789388
[TBL] [Abstract][Full Text] [Related]
47. Salt formation improved the properties of a candidate drug during early formulation development.
Sigfridsson K; Ahlqvist M; Lindsjö M; Paulsson S
Eur J Pharm Sci; 2018 Jul; 120():162-171. PubMed ID: 29730322
[TBL] [Abstract][Full Text] [Related]
48. Solid-state characterization of tacrine hydrochloride.
Sorrenti M; Catenacci L; Bruni G; Luppi B; Bigucci F; Bettinetti G
J Pharm Biomed Anal; 2012 Apr; 63():53-61. PubMed ID: 22326286
[TBL] [Abstract][Full Text] [Related]
49. Naproxen particle design using porous starch.
Nagata K; Okamoto H; Danjo K
Drug Dev Ind Pharm; 2001 Apr; 27(4):287-96. PubMed ID: 11411896
[TBL] [Abstract][Full Text] [Related]
50. In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine.
Kasten G; Lobo L; Dengale S; Grohganz H; Rades T; Löbmann K
Eur J Pharm Biopharm; 2018 Nov; 132():192-199. PubMed ID: 30266670
[TBL] [Abstract][Full Text] [Related]
51. Effects of particle morphology, pore size and surface coating of mesoporous silica on Naproxen dissolution rate enhancement.
Guo Z; Liu XM; Ma L; Li J; Zhang H; Gao YP; Yuan Y
Colloids Surf B Biointerfaces; 2013 Jan; 101():228-35. PubMed ID: 23010024
[TBL] [Abstract][Full Text] [Related]
52. Properties of the Sodium Naproxen-Lactose-Tetrahydrate Co-Crystal upon Processing and Storage.
Sovago I; Wang W; Qiu D; Raijada D; Rantanen J; Grohganz H; Rades T; Bond AD; Löbmann K
Molecules; 2016 Apr; 21(4):509. PubMed ID: 27104502
[TBL] [Abstract][Full Text] [Related]
53. Physicochemical stability of cimetidine amorphous forms estimated by isothermal microcalorimetry.
Otsuka M; Kato F; Matsuda Y
AAPS PharmSciTech; 2002; 3(4):E30. PubMed ID: 12916924
[TBL] [Abstract][Full Text] [Related]
54. Physicochemical and mechanical properties of carbamazepine cocrystals with saccharin.
Rahman Z; Samy R; Sayeed VA; Khan MA
Pharm Dev Technol; 2012; 17(4):457-65. PubMed ID: 21265708
[TBL] [Abstract][Full Text] [Related]
55. Preparation and recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin.
Beyer A; Radi L; Grohganz H; Löbmann K; Rades T; Leopold CS
Eur J Pharm Biopharm; 2016 Jul; 104():72-81. PubMed ID: 27130786
[TBL] [Abstract][Full Text] [Related]
56. Solid-state characterization of chlordiazepoxide polymorphs.
Singh D; Marshall PV; Shields L; York P
J Pharm Sci; 1998 May; 87(5):655-62. PubMed ID: 9572919
[TBL] [Abstract][Full Text] [Related]
57. Crystal modifications and dissolution rate of piroxicam.
Lyn LY; Sze HW; Rajendran A; Adinarayana G; Dua K; Garg S
Acta Pharm; 2011 Dec; 61(4):391-402. PubMed ID: 22202198
[TBL] [Abstract][Full Text] [Related]
58. Effect of PEG 4000 on the dissolution rate of naproxen.
Vélaz I; Sánchez M; Martín C; Martínez-Ohárriz MC
Eur J Drug Metab Pharmacokinet; 1998; 23(2):103-8. PubMed ID: 9725465
[TBL] [Abstract][Full Text] [Related]
59. Use of SBA-15 for furosemide oral delivery enhancement.
Ambrogi V; Perioli L; Pagano C; Marmottini F; Ricci M; Sagnella A; Rossi C
Eur J Pharm Sci; 2012 May; 46(1-2):43-8. PubMed ID: 22365882
[TBL] [Abstract][Full Text] [Related]
60. Wet milling induced physical and chemical instabilities of naproxen nano-crystalline suspensions.
Kumar S; Burgess DJ
Int J Pharm; 2014 May; 466(1-2):223-32. PubMed ID: 24614581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
